Page 2 - Sciences Press News Today

TORRANCE, Calif., May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration... | June 7, 2023

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received Registration Approval...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received Registration Approval...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...

This week, the editors revisit writer-artist Constance DeJong’s “In Between the Dark and the Light,” a piece published in January 1981 on “Television/Society/Art,” a symposium held at the Kitchen in New York City the prior autumn. DeJong’s Reader (Primary Information), an anthology of eighteen texts including out-of-print and unpublished works, is in bookstores now.Before the internet, television was of course the messiah-bogeyman of consequence, promising liberation via the democra...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...